Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hallucinogens
Biotech
MindMed links LSD to reduced anxiety in phase 2b, plots phase 3
Patients in some of the phase 2b dose cohorts experienced reductions in anxiety that persisted through the four-week trial.
Nick Paul Taylor
Dec 14, 2023 9:32am
Psilocybin clears biggest test yet, easing depression in phase 2
Nov 10, 2021 7:30am
Psychedelics inch toward approval, but market may not be ready
Aug 17, 2021 10:40am
Investors are tripping on psychedelics despite murky path ahead
Aug 16, 2021 9:50am
Journey debuts with $3M, new development model for psychedelics
Oct 26, 2020 3:14pm
